Biotechs are lining up for $269M in fresh IPO funding amid a sector rebound. The market’s appetite for biotech IPOs has ebbed and flowed since the onset of last year’s boom, and, after a trying respite in May, investors now seem to be all ears to convincing stories in drug development … more